These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 7526571)

  • 1. Analysis of epitopic residues introduced into the hybrid peptide vaccines prepared according to the cassette theory.
    Naruse H; Ogasawara K; Takami K; Kajino K; Gotohda T; Itoh Y; Miyazaki T; Good RA; Onoè K
    Vaccine; 1994 Jul; 12(9):776-82. PubMed ID: 7526571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A potential peptide vaccine against two different strains of influenza virus isolated at intervals of about 10 years.
    Naruse H; Ogasawara K; Kaneda R; Hatakeyama S; Itoh T; Kida H; Miyazaki T; Good RA; Onoé K
    Proc Natl Acad Sci U S A; 1994 Sep; 91(20):9588-92. PubMed ID: 7937811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development of synthetic peptide vaccine against influenza--T cell epitope the hemagglutinin of A/Aichi/2/68(H3N2) influenza virus induced immune response in mice].
    Naruse H
    Hokkaido Igaku Zasshi; 1994 Jul; 69(4):811-20. PubMed ID: 7525436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of infection of influenza virus in DQ6 mice, a human model, by a peptide vaccine prepared according to the cassette theory.
    Matsuki N; Ogasawara K; Takami K; Namba K; Takahashi A; Fukui Y; Sasazuki T; Iwabuchi K; Good RA; Onoé K
    Vaccine; 1999 Mar; 17(9-10):1161-8. PubMed ID: 10195628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of the agretopic residues of a peptide co-restricted to different class II isotypes, I-Au and I-Eu, and its application for preparation of a synthetic peptide vaccine against influenza virus A/Aichi/2/68.
    Takami K; Ogasawara K; Itoh Y; Kajino K; Naruse H; Onoé K
    Microbiol Immunol; 1994; 38(10):779-87. PubMed ID: 7532781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A strategy for making synthetic peptide vaccines.
    Ogasawara K; Naruse H; Itoh Y; Gotohda T; Arikawa J; Kida H; Good RA; Onoé K
    Proc Natl Acad Sci U S A; 1992 Oct; 89(19):8995-9. PubMed ID: 1409595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [An investigation of the effect of H3-H3 peptide vaccine for preventing influenza virus infection in DQ6 mice].
    Matsuki N
    Hokkaido Igaku Zasshi; 1998 Mar; 73(2):171-9. PubMed ID: 9612710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective induction of protection against influenza virus infection in mice by a lipid-peptide conjugate delivered in liposomes.
    Friede M; Muller S; Briand JP; Plaué S; Fernandes I; Frisch B; Schuber F; Van Regenmortel MH
    Vaccine; 1994 Jul; 12(9):791-7. PubMed ID: 7975857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Determination of a peptide deduced from the influenza virus haemagglutinin that induces human class II-restricted T cell responses in DQ6 transgenic mice].
    Takami K
    Hokkaido Igaku Zasshi; 1995 Mar; 70(2):329-42. PubMed ID: 7774884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The intersubunit region of the influenza virus haemagglutinin is recognized by antibodies during infection.
    Nagy Z; Rajnavölgyi E; Hollósi M; Tóth GK; Váradi G; Penke B; Tóth I; Horváth A; Gergely J; Kurucz I
    Scand J Immunol; 1994 Sep; 40(3):281-91. PubMed ID: 8091127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune response of human volunteers and animals to vaccination with egg-grown influenza A (H1N1) virus is influenced by three amino acid substitutions in the haemagglutinin molecule.
    Newman RW; Jennings R; Major DL; Robertson JS; Jenkins R; Potter CW; Burnett I; Jewes L; Anders M; Jackson D
    Vaccine; 1993; 11(4):400-6. PubMed ID: 8470424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of recombinant influenza virus haemagglutinin carrying peptides from the envelope protein of human immunodeficiency virus type 1.
    Kalyan NK; Lee SG; Wilhelm J; Pisano MR; Hum WT; Hsiao CL; Davis AR; Eichberg JW; Robert-Guroff M; Hung PP
    Vaccine; 1994 Jun; 12(8):753-60. PubMed ID: 7522383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A lipopeptide based on the M2 and HA proteins of influenza A viruses induces protective antibody.
    Pejoski D; Zeng W; Rockman S; Brown LE; Jackson DC
    Immunol Cell Biol; 2010 Jul; 88(5):605-11. PubMed ID: 20177411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The immunological activity of a deletion mutant of influenza virus haemagglutinin lacking the globular region.
    Sagawa H; Ohshima A; Kato I; Okuno Y; Isegawa Y
    J Gen Virol; 1996 Jul; 77 ( Pt 7)():1483-7. PubMed ID: 8757990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Induction of neutralizing antibodies against HIV-1 viruses in HLA-DQ6 mice by peptide vaccines].
    Takahashi A
    Hokkaido Igaku Zasshi; 1998 Mar; 73(2):147-56. PubMed ID: 9612708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Presentation by a major histocompatibility complex class I molecule of nucleoprotein peptide expressed in two different genes of an influenza virus transfectant.
    Isobe H; Moran T; Li S; Young A; Nathenson S; Palese P; Bona C
    J Exp Med; 1995 Jan; 181(1):203-13. PubMed ID: 7528768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A peptide-based human T cell leukemia virus type I vaccine containing T and B cell epitopes that induces high titers of neutralizing antibodies.
    Baba E; Nakamura M; Ohkuma K; Kira J; Tanaka Y; Nakano S; Niho Y
    J Immunol; 1995 Jan; 154(1):399-412. PubMed ID: 7527817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD40-mediated enhancement of immune responses against three forms of influenza vaccine.
    Hatzifoti C; Heath AW
    Immunology; 2007 Sep; 122(1):98-106. PubMed ID: 17472718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric peptides: a new approach to enhancing the immunogenicity of peptides with low MHC class I affinity: application in antiviral vaccination.
    Tourdot S; Oukka M; Manuguerra JC; Magafa V; Vergnon I; Riché N; Bruley-Rosset M; Cordopatis P; Kosmatopoulos K
    J Immunol; 1997 Sep; 159(5):2391-8. PubMed ID: 9278330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.